REATA PHARMACEUTICALS INC Quarterly Nonoperating Income (Expense) in USD from Q1 2015 to Q2 2023

Taxonomy & unit: us-gaap: USD
Description: The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
Summary: Reata Pharmaceuticals Inc quarterly/annual Nonoperating Income (Expense) history and growth rate from Q1 2015 to Q2 2023.
Reata Pharmaceuticals Inc Nonoperating Income (Expense) for the quarter ending June 30, 2023 was $285M.
Reata Pharmaceuticals Inc Nonoperating Income (Expense) for the twelve months ending June 30, 2023 was $265M.
Reata Pharmaceuticals Inc annual Nonoperating Income (Expense) for 2022 was -$33.9M, a 36.2% increase from 2021.
Reata Pharmaceuticals Inc annual Nonoperating Income (Expense) for 2021 was -$53.1M, a 21% decline from 2020.
Reata Pharmaceuticals Inc annual Nonoperating Income (Expense) for 2020 was -$43.9M, a 789% decline from 2019.

Nonoperating Income (Expense), Trailing 12 Months (USD)

Nonoperating Income (Expense), Quarterly (USD)

Nonoperating Income (Expense), YoY Quarterly Growth (%)

Period	TTM Value	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed
Q2 2023	$265M	$285M	+$295M		Apr 1, 2023	Jun 30, 2023	10-Q	2023-08-08
Q1 2023	-$29.8M	-$5.66M	+$4.11M	+42.1%	Jan 1, 2023	Mar 31, 2023	10-Q	2023-05-10
Q4 2022	-$33.9M	-$6.03M	+$7.56M	+55.6%	Oct 1, 2022	Dec 31, 2022	10-K	2023-02-24
Q3 2022	-$41.5M	-$8.52M	+$5.24M	+38.1%	Jul 1, 2022	Sep 30, 2022	10-Q	2022-11-08
Q2 2022	-$46.7M	-$9.57M	+$3.65M	+27.6%	Apr 1, 2022	Jun 30, 2022	10-Q	2023-08-08
Q1 2022	-$50.3M	-$9.77M	+$2.78M	+22.2%	Jan 1, 2022	Mar 31, 2022	10-Q	2023-05-10
Q4 2021	-$53.1M	-$13.6M	-$1.65M	-13.8%	Oct 1, 2021	Dec 31, 2021	10-K	2023-02-24
Q3 2021	-$51.5M	-$13.8M	-$2.59M	-23.2%	Jul 1, 2021	Sep 30, 2021	10-Q	2022-11-08
Q2 2021	-$48.9M	-$13.2M	+$3.77M	+22.2%	Apr 1, 2021	Jun 30, 2021	10-Q	2022-08-08
Q1 2021	-$52.7M	-$12.6M	-$8.74M	-229%	Jan 1, 2021	Mar 31, 2021	10-Q	2022-05-10
Q4 2020	-$43.9M	-$11.9M	-$9.38M	-366%	Oct 1, 2020	Dec 31, 2020	10-K	2021-03-01
Q3 2020	-$34.5M	-$11.2M	-$10.1M	-936%	Jul 1, 2020	Sep 30, 2020	10-Q	2021-11-08
Q2 2020	-$24.4M	-$17M	-$16.3M	-2324%	Apr 1, 2020	Jun 30, 2020	10-Q	2021-08-09
Q1 2020	-$8.16M	-$3.81M	-$3.21M	-536%	Jan 1, 2020	Mar 31, 2020	10-Q	2021-05-06
Q4 2019	-$4.94M	-$2.56M	-$1.91M	-295%	Oct 1, 2019	Dec 31, 2019	10-K	2021-03-01
Q3 2019	-$3.03M	-$1.08M	+$188K	+14.9%	Jul 1, 2019	Sep 30, 2019	10-K	2021-03-01
Q2 2019	-$3.22M	-$701K	+$852K	+54.9%	Apr 1, 2019	Jun 30, 2019	10-K	2021-03-01
Q1 2019	-$4.07M	-$600K	-$426K	-245%	Jan 1, 2019	Mar 31, 2019	10-K	2021-03-01
Q4 2018	-$3.64M	-$649K	-$501K	-339%	Oct 1, 2018	Dec 31, 2018	10-K	2020-02-19
Q3 2018	-$3.14M	-$1.27M	-$977K	-338%	Jul 1, 2018	Sep 30, 2018	10-K	2020-02-19
Q2 2018	-$2.16M	-$1.55M	-$1.16M	-293%	Apr 1, 2018	Jun 30, 2018	10-K	2020-02-19
Q1 2018	-$1.01M	-$174K	-$250K	-329%	Jan 1, 2018	Mar 31, 2018	10-K	2020-02-19
Q4 2017	-$756K	-$148K	-$249K	-247%	Oct 1, 2017	Dec 31, 2017	10-K	2019-02-28
Q3 2017	-$507K	-$289K	-$351K	-566%	Jul 1, 2017	Sep 30, 2017	10-K	2019-02-28
Q2 2017	-$156K	-$395K	-$423K	-1511%	Apr 1, 2017	Jun 30, 2017	10-K	2019-02-28
Q1 2017	$267K	$76K	+$53K	+230%	Jan 1, 2017	Mar 31, 2017	10-K	2019-02-28
Q4 2016	$214K	$101K	+$94K	+1343%	Oct 1, 2016	Dec 31, 2016	10-K	2018-03-02
Q3 2016	$120K	$62K	+$53K	+589%	Jul 1, 2016	Sep 30, 2016	10-K	2018-03-02
Q2 2016	$67K	$28K	+$20K	+250%	Apr 1, 2016	Jun 30, 2016	10-K	2018-03-02
Q1 2016	$47K	$23K	+$15K	+188%	Jan 1, 2016	Mar 31, 2016	10-K	2018-03-02
Q4 2015	$32K	$7K			Oct 1, 2015	Dec 31, 2015	10-K	2017-03-03
Q3 2015		$9K			Jul 1, 2015	Sep 30, 2015	10-K	2017-03-03
Q2 2015		$8K			Apr 1, 2015	Jun 30, 2015	10-K	2017-03-03
Q1 2015		$8K			Jan 1, 2015	Mar 31, 2015	10-K	2017-03-03

* An asterisk sign (*) next to the value indicates that the value is likely invalid.